Dr. Peppa

Is BPC-157 legal? What the FDA record says as of September 2026

Published by Dr. Peppa ·

Disclosure: Dr. Peppa is owned and operated by Medtruva LLC, which sells peptide products, including some compounds discussed on this site. Advertisements are labeled.

The short answer

  • Not an approved drug. No FDA-approved medicine contains BPC-157, for any condition.
  • Not compoundable today. Pharmacies can't legally use it to make medications.
  • A July 2026 advisory vote recommended allowing it. That recommendation is non-binding, and as of September 2026 no rule has followed.
  • Banned in sport since 2022.

What "legal" means here

Three separate questions get mixed together in online discussions. They have different answers.

  1. Is it an approved drug? No.
  2. Can a pharmacy compound it for a patient? Not right now.
  3. Can a company sell it? Selling it for human use is illegal, and FDA has acted on that.

1. It is not an approved drug

There is no FDA-approved product containing BPC-157. FDA's July 2026 briefing document on the compound also notes that its molecular targets "have not been identified."

The human research is thin. FDA's own review lists a handful of human reports, the main one being a conference abstract in 53 people with ulcerative colitis, given as an enema rather than an injection.

2. Compounding: the status changed twice in three years

Compounding pharmacies can only use bulk ingredients that appear on an FDA list, or that meet other narrow conditions. BPC-157's position on that list has moved:

That vote did not make it legal. Advisory committees make non-binding recommendations. Adding a substance to the list requires formal rulemaking with a public comment period. As of September 20, 2026, no proposed or final rule has been published.

3. Selling it: FDA has been acting

Vendors commonly sell BPC-157 labeled "for research use only" or "not for human consumption." FDA's position is that the label doesn't decide what a product legally is — the marketing does.

On August 24, 2026, FDA issued warning letters to several peptide sellers, treating their products as unapproved new drugs. The letters quote the sellers' own websites describing what the compounds are "researched for" as evidence the products were intended for people.

Oral BPC-157 capsules sold as dietary supplements sit on similarly shaky ground. Federal law excludes from the definition of a dietary supplement any article that was first investigated as a drug, and BPC-157 was investigated as a drug in the early 2000s.

4. Sport: prohibited

BPC-157 was added to the World Anti-Doping Agency's Prohibited List in 2022 under the non-approved substances category, which applies at all times, in and out of competition. Detection methods have been published.

What could change, and when

The advisory committee's recommendation goes to FDA, which can accept, modify or ignore it. If FDA moves forward, the next visible step is a proposed rule in the Federal Register, followed by a comment period. There's no published timeline.

Separately, state medical boards have been acting on their own. Alabama and Mississippi issued notices in 2026 about physicians prescribing research-grade peptides, and state rules can be stricter than federal ones.

Sources